Integra LifeSciences Shares Drop Amid Revenue Shortfall; Investigation Launched

NEW YORK, Oct. 2, 2026 – Shares of Integra LifeSciences (NASDAQ: IART) experienced a sharp decline on October 2, 2026, following the company's announcement of preliminary third-quarter revenue figures that fell short of analyst expectations. The company reported revenue between $410 million and $412 million, missing the FactSet consensus estimate of $416.3 million. The stock price dropped as much as 20% during intraday trading.

In addition to the quarterly miss, Integra LifeSciences revised its full-year revenue guidance downwards. The company now projects revenue between $1.634 billion and $1.654 billion, a reduction from its previous forecast of $1.654 billion to $1.695 billion. Integra attributed the shortfall primarily to a flooding incident at its Cincinnati facility in July 2026, which it estimates negatively impacted third-quarter revenue by approximately $7 million and is expected to reduce fourth-quarter revenue by an additional $15 million to $20 million. The company anticipates a return to full manufacturing operations not before the second quarter of 2027.

This downward revision comes after the company previously stated the flooding would not have a material impact on its financial guidance. During a July 29, 2026 earnings call, Chief Financial Officer Lea Daniels Knight indicated the event would not significantly affect revenue or earnings per share guidance for 2026. The discrepancy has prompted a securities investigation by SueWallSt, which is examining potential claims for shareholders who have incurred losses.

Integra LifeSciences is a medical technology company that develops, manufactures, and markets medical devices used in a variety of applications, including neurosurgery, spinal procedures, and general surgery. The recent disclosures highlight the challenges companies can face from unforeseen operational disruptions and their impact on financial performance and investor confidence.